Valuation : BioRestorative Therapies, Inc.

Market Cap 3.77M 3.24M 3.05M 2.79M 5.22M 356M 5.23M 36.07M 14M 183M 14.16M 13.85M 588M P/E 2026 *
-0.3x
P/E 2027 * -0.37x
Enterprise Value 3.77M 3.24M 3.05M 2.79M 5.22M 356M 5.23M 36.07M 14M 183M 14.16M 13.85M 588M EV / Sales 2026 *
2.68x
EV / Sales 2027 * 1.63x
Free-Float
89.63%
Yield 2026 *
-
Yield 2027 * -
1 day+2.99%
1 week-25.67%
Current month-26.88%
1 month-29.52%
3 months-64.28%
6 months-31.92%
Current year-87.40%
1 week 0.14
Extreme 0.1425
0.21
1 month 0.14
Extreme 0.1425
0.24
Current year 0.14
Extreme 0.1425
1.28
1 year 0.14
Extreme 0.1425
1.73
3 years 0.14
Extreme 0.1425
3.67
5 years 0.14
Extreme 0.1425
24
10 years 0.14
Extreme 0.1425
20,040
Manager TitleAgeSince
Chief Executive Officer 28 26/08/2026
Director of Finance/CFO 38 26/08/2026
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 37 11/06/2026
Director/Board Member - 12/07/2026
Director/Board Member 28 11/06/2026
Date Insider Type Main position Quantity % Market Cap. Importance
06/10/25 Free

Chief Technology Officer

23,438 0.2938%
06/10/25 Free

Chief Executive Officer

27,344 0.3427%
14/02/25 Other

Chief Technology Officer

768,979 11.1125%
Change 5-day change 1-year change 3-year change Capi.($)
+2.99%-25.67%-90.92%-93.57% 3.66M
-1.79%-2.27%+50.90%+89.03% 69.02B
-2.06%-0.18%+41.53%+88.17% 66.32B
-0.31%+6.54%-11.39%+457.82% 27.66B
-3.00%-2.90%+39.40%+9.41% 26.54B
+0.86%+1.65%+0.25%-14.78% 25.84B
-1.46%+0.42%+24.07%-18.70% 20.4B
-2.96%-15.21%+210.71%+370.84% 17.63B
-1.49%-4.88%-0.41%+530.26% 15.15B
-0.20%+8.37%+57.87%+159.50% 14.65B
Average -0.94%-2.88%+32.20%+157.80% 28.32B
Weighted average by Cap. -1.53%-0.34%+42.55%+144.94%

Financials

2026 *2027 *
Net sales 1.4M 1.21M 1.14M 1.04M 1.94M 133M 1.95M 13.44M 5.22M 68.06M 5.28M 5.16M 219M 2.31M 1.99M 1.87M 1.71M 3.2M 218M 3.21M 22.12M 8.58M 112M 8.68M 8.49M 361M
Net income -13.52M -11.64M -10.95M -10M -18.71M -1.28B -18.76M -129M -50.2M -655M -50.78M -49.67M -2.11B -15.56M -13.39M -12.6M -11.51M -21.53M -1.47B -21.58M -149M -57.76M -754M -58.42M -57.15M -2.43B
Net Debt - -
Logo BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.
Employees
14
Date Price Change Volume
04/09/26 US$0.1480 +2.99% 765,782
03/09/26 US$0.1437 -28.76% 3,514,377
02/09/26 US$0.2017 +1.74% 489,292
01/09/26 US$0.1983 -2.05% 174,808
31/08/26 US$0.2024 +1.66% 216,168
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.1480USD
Average target price
8.000USD
Spread / Average Target
+5,305.41%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BRTX Stock